Raw material bottlenecks in cell & gene therapy

The quality, supply and reliability of raw materials can cause delays, spiralling costs and can even derail clinical development programs. You need consistency and trusted partners to ease these bottlenecks and get the best results.

We’ve taken the pulse of the industry in a recent survey to better understand the biggest raw materials challenges when bringing a cell and gene therapy product through clinical development to commercial scale.

55% said that the supply of high-grade, consistent raw materials is their biggest challenge.

Here are some of the other bottlenecks:

  • Variation between lots
  • Preclinical to GMP transition
  • Unreliable supply
  • Finding contingency suppliers
  • Measuring activity and function
  • Comparability studies

What are the most pressing raw materials challenges for you right now?

We’ve put all the results into this infographic to provide you with insights and a benchmark against the wider industry, take a look at the infographic here